临床与病理杂志2023，Vol.43Issue(10)：1848-1856,9.DOI:10.11817/j.issn.2095-6959.2023.230091
成纤维细胞活化蛋白在肿瘤诊断及治疗中的研究进展
Research progress of fibroblast activation protein in tumors diagnosis and treatment
摘要
Abstract
Fibroblast activation protein(FAP)is one of the specific markers of carcinoma-associated fibroblasts(CAFs),which is generally not expressed in normal tissues and non-malignant tumors but is highly expressed in CAFs derived from the majority of malignant tumors of epithelial cell origin.FAP can be used as a specific tumor marker and has a high research value in the clinical diagnosis and treatment of hepatocellular carcinoma(HCC),pancreatic cancer,breast cancer,and oral cancer.Targeted treatment strategies for FAP include FAP inhibition,FAPI),FAP enzyme-activated prodrugs,FAP vaccines,FAP antibodies and chimeric antigen receptor T cell immuno-therapy(CAR-T).Their mechanisms of action are mainly reflected in:1)Targeted inhibition of FAP activity to suppress tumor growth;2)eliminate stroma-tumor cell interactions,especially in solid tumors,to increase intratumoral drug delivery and enhance the activity of immunotherapy drugs.The study of FAP in the diagnosis and treatment of tumors can provide reference value for related clinical research,and help to improve the efficiency of clinical diagnosis and treatment of tumors and the quality of life of patients,prolong the overall survival and reduce complications.关键词
成纤维细胞活化蛋白/肿瘤/诊断/治疗Key words
fibroblast activation protein/tumor/diagnosis/treatment引用本文复制引用
李菀婷,吴颖彤,郑黔莉,王檬,田张瑶,田林露,钱滢滢,杨文利..成纤维细胞活化蛋白在肿瘤诊断及治疗中的研究进展[J].临床与病理杂志,2023,43(10):1848-1856,9.基金项目
贵州省大学生创新创业项目(S202210661013) （S202210661013）
遵义医科大学博士科研基金(F-ZH-09) （F-ZH-09）
遵义医科大学珠海校区大学生创新创业项目(ZHCX202113,ZHCX2022039).This work was supported by the Innovation and Entrepreneurship Project for College Students in Guizhou Province(S202210661013),the Zunyi Medical University Doctoral Research Fund(F-ZH-09),and the Innovation and Entrepreneurship Program for College Students at Zhuhai Campus of Zunyi Medical University(ZHCX202113,ZHCX2022039),China. （ZHCX202113,ZHCX2022039）
